As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

I'm a clinical academic, which is quite a rare breed of doctor, because what I'm doing, along with other clinical academics, ...

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

Aubrey Barnett, 17, graduated from Walnut Grove High School just five months after finishing chemotherapy and ringing the ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

King Charles was diagnosed with cancer in February 2024, following treatment for an enlarged prostate. Since then, he has ...

Treatment with retifanlimab plus carboplatin-paclitaxel statistically significantly reduced the risk of progression or death by 37% compared with placebo plus carboplatin-paclitaxel.

Mature overall survival results of the INAVO120 trial were presented in a press conference for the American Society of ...

Depending on tumor location, presurgical radiation can improve overall survival, but that option comes with an increased risk ...

Carolyn Collins endured two decades of treatment. Now cancer-free, she reflects on her journey of faith and perseverance.

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...